Search Product
Structure Search
Search
Advantage Products
Location: Industrial Info
New use for old drug: propranolol may have anti-cancer effect
2016-10-17
来源:转载自第三方
17 October 2016
On October 12th, "Ecancer Medical Science" published an article, "Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent" [1], claimed the drugs propranolol (PRO) treat arrhythmia also has significant anti-cancer properties.
Propranolol, chemical name 1-isopropylamino-3-(1-naphthyloxy)-2-propanol, can be synthesized from naphthol, epichlorohydrin and isopropylamine for the treatment of arrhythmia, sinus and supraventricular tachycardia, atrial fibrillation, angina, hypertension and myocardial infarction due to a variety of causes.
In addition to clinical indications, there is growing evidence that PRO also has anti-cancer effects. In fact, as early as the 1960s, the drug has record for effective treatment of infantile hemangioma, but until a few years ago, only careful doctors found the drug’s characteristics, the drug also has the possibility to treat other types of cancer. The researchers said that PRO are effective for cancer-related immune system cell proliferation and invasion. According to the existing human and animal clinical application data, in many types of cancer treatment assessment, PRO have shown a remarkable good characteristics. There are still more trials underway in order to treat various cancers with different therapies through PRO.
Researchers have conducted a number of related academic research on PRO, and also explored possible new treatments, as a very powerful anticancer agent candidate drug. In the anti-transfer after surgical treatment and in combination with other drugs, PRO is likely to be the future research direction.
References
[1] Pan Pantziarka, Gauthier Bouche, Vidula Sukhatme. Repurposing Drugs in Oncology (ReDO) -Propranolol as an anti-cancer agent. Ecancer Medical Science, 2016, doi: 10.3332/ecancer.2016.680.
Related Links: Naphthol
Edited by Suzhou Yacoo Science Co., Ltd.
如果涉及转载授权,请联系我们。